Trial Profile
Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Eribulin (Primary)
- Indications Advanced breast cancer; Brain metastases
- Focus Therapeutic Use
- 20 Jul 2020 Status has been changed to completed.
- 03 Jun 2019 Results published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019).
- 03 Jun 2019 Status changed from active, no longer recruiting to discontinued, as the study was closed due to slow accrual, according to the Results published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019).